The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Risperidal     3-[2-[4-(6- fluorobenzo[d]isoxazol-3-yl)- 1...

Synonyms: risperidone, R-64766, R-64,766, R64766, R 64766, ...
 Lang,  Ulmschneider,  Koenig,  Rui,  Mahmoud,  Price,  Thase,  Zhang,  Miyahara,  Labelle,  Kim,  Scheppach,  Eriksson,  Allison,  Zhou, Keith Karcher,  Brandstätter,  Miklowitz,  Scordo,  Holmes,  Pantelis,  Labelle,  McCracken,  Tollefson,  Perucca,  Vandorpe,  Sokullu,  Carlson,  Shen,  Barton,  Vitiello,  Kapur,  Bergman,  Robinson,  McDougle,  McDougle,  Kabir,  Richey,  Kane,  Möller,  Ghuman,  Shammi,  Dineen,  Remington, Akbar Khan,  Mann,  Goldman,  Sevy,  Aman,  Smith,  Pan,  Ali,  Halldin,  Honer,  Kujawa,  Pelton,  McGough,  Chuang,  Stock,  Ritz,  Addington,  Purdon,  Bauer,  Arnold,  Ader,  David,  Davies,  Mamo,  Tierney,  Susce,  Goff,  Oxenstierna,  Goghari,  Fairchild,  Marangell,  Marder,  Catalano,  Gonzalez,  Avenoso,  Calabrese,  Hollway,  Cohen,  Hucking,  Stip,  Swiezy,  Nyberg,  Ostacher,  Carson,  Wu, Nicholas A. Keks,  Zhang,  Hayden,  Martin,  Morrison,  Farde,  Ionut,  Henderson,  Evins,  Ekholm,  Malhotra,  Weber,  Müller,  Daley,  Kopala,  Koch,  Wisniewski,  Posey,  Saha,  Lencz,  Krampe,  Lapointe,  Ancione,  Anderson,  Reiss,  Copeland,  Borba,  Stringfellow,  Engel,  Potkin,  Benattia,  Schwarz,  Breier, Chadi A. Calarge, Vicki L. Ellingrod, Laura Acion, Del D. Miller, Jessica Moline, Michael J. Tansey, Janet A. Schlechte,  Addington,  Romano,  Gunduz-Bruce,  Ketter,  Woerner,  Cao,  Cagliero,  Spina,  Scahill, Michael Ingham,  Cottingham,  Riedel,  Xu,  Gatti,  Ingenito,  Jones,  Mannaert,  Shah,  de Leon,  Csernansky,  Nierenberg,  Sachs,  Schoenfeld,  Brenner,  Wedlund,  Madia,  
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of risperidone


Psychiatry related information on risperidone


High impact information on risperidone


Chemical compound and disease context of risperidone


Biological context of risperidone

  • We examined the effects of atypical antipsychotics olanzapine (OLZ) and risperidone (RIS) versus placebo on adiposity, insulin sensitivity (S(I)), and pancreatic beta-cell compensation [17].
  • Risperidone for the core symptom domains of autism: results from the study by the autism network of the research units on pediatric psychopharmacology [18].
  • OBJECTIVE: This study assessed the impact of risperidone on growth and sexual maturation [19].
  • Peripheral markers of bone formation and resorption were used to measure bone metabolism in 14 Caucasian female patients with schizophrenia treated with risperidone or olanzapine monotherapy over 12 months [20].
  • METHOD: Patients experiencing their first episode of schizophrenia (N=61) were genotyped for two DRD2 promoter region polymorphisms (A-241G and -141C Ins/Del) and were randomly assigned to receive 16 weeks of treatment with either risperidone or olanzapine [21].

Anatomical context of risperidone


Associations of risperidone with other chemical compounds


Gene context of risperidone


Analytical, diagnostic and therapeutic context of risperidone

  • METHODS: Sixty-five patients in this multicenter double-blind study were randomly assigned to olanzapine (5-20 mg), risperidone (4-10 mg), or haloperidol (5-20 mg) [35].
  • Thirty-six nonobese subjects with schizophrenia or schizoaffective disorder, matched by body mass index and treated with either clozapine, olanzapine, or risperidone, were included in the analysis [11].
  • OBJECTIVE: To study the 2 drugs most clearly implicated (clozapine and olanzapine) and risperidone using a frequently sampled intravenous glucose tolerance test [11].
  • This study provides direct evidence for significantly enhanced frontal function in schizophrenic patients after substitution of risperidone for typical antipsychotic drugs, and it indicates the potential value of functional MRI as a tool for longitudinal assessment of psychopharmacological effects on cerebral physiology [22].
  • OBJECTIVE: Long-acting injectable risperidone represents the first clinically available depot atypical antipsychotic [36].


  1. Risperidone and neuroleptic malignant syndrome. Tarsy, D. JAMA (1996) [Pubmed]
  2. Risperidone in Parkinson's disease. Ford, B., Lynch, T., Greene, P. Lancet (1994) [Pubmed]
  3. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Potkin, S.G., Saha, A.R., Kujawa, M.J., Carson, W.H., Ali, M., Stock, E., Stringfellow, J., Ingenito, G., Marder, S.R. Arch. Gen. Psychiatry (2003) [Pubmed]
  4. Tardive dyskinesia with risperidone and anticholinergics. Suzuki, E., Obata, M., Yoshida, Y., Miyaoka, H. The American journal of psychiatry. (2002) [Pubmed]
  5. Risperidone-induced hyperprolactinemia in an elderly woman. Bai, Y.M., Ciu, H.J., Guo, Z.Z. The American journal of psychiatry. (2002) [Pubmed]
  6. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. Csernansky, J.G., Mahmoud, R., Brenner, R. N. Engl. J. Med. (2002) [Pubmed]
  7. Neuroleptic sensitivity to risperidone in Lewy body dementia. McKeith, I.G., Ballard, C.G., Harrison, R.W. Lancet (1995) [Pubmed]
  8. Risperidone for Tourette's syndrome. Stamenkovic, M., Aschauer, H., Kasper, S. Lancet (1994) [Pubmed]
  9. A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders. McDougle, C.J., Holmes, J.P., Carlson, D.C., Pelton, G.H., Cohen, D.J., Price, L.H. Arch. Gen. Psychiatry (1998) [Pubmed]
  10. Risperidone-induced tardive dystonia and psychosis. Vercueil, L., Foucher, J. Lancet (1999) [Pubmed]
  11. Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis. Henderson, D.C., Cagliero, E., Copeland, P.M., Borba, C.P., Evins, E., Hayden, D., Weber, M.T., Anderson, E.J., Allison, D.B., Daley, T.B., Schoenfeld, D., Goff, D.C. Arch. Gen. Psychiatry (2005) [Pubmed]
  12. Metformin for weight loss in pediatric patients taking psychotropic drugs. Morrison, J.A., Cottingham, E.M., Barton, B.A. The American journal of psychiatry. (2002) [Pubmed]
  13. Treatment-resistant bipolar depression: a STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol, or risperidone. Nierenberg, A.A., Ostacher, M.J., Calabrese, J.R., Ketter, T.A., Marangell, L.B., Miklowitz, D.J., Miyahara, S., Bauer, M.S., Thase, M.E., Wisniewski, S.R., Sachs, G.S. The American journal of psychiatry. (2006) [Pubmed]
  14. Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia. Müller, N., Riedel, M., Scheppach, C., Brandstätter, B., Sokullu, S., Krampe, K., Ulmschneider, M., Engel, R.R., Möller, H.J., Schwarz, M.J. The American journal of psychiatry. (2002) [Pubmed]
  15. Efficacy and tolerability of ziprasidone versus risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder: an 8-week, double-blind, multicenter trial. Addington, D.E., Pantelis, C., Dineen, M., Benattia, I., Romano, S.J. The Journal of clinical psychiatry. (2004) [Pubmed]
  16. Inhibition of risperidone metabolism by fluoxetine in patients with schizophrenia: a clinically relevant pharmacokinetic drug interaction. Spina, E., Avenoso, A., Scordo, M.G., Ancione, M., Madia, A., Gatti, G., Perucca, E. Journal of clinical psychopharmacology. (2002) [Pubmed]
  17. Metabolic dysregulation with atypical antipsychotics occurs in the absence of underlying disease: a placebo-controlled study of olanzapine and risperidone in dogs. Ader, M., Kim, S.P., Catalano, K.J., Ionut, V., Hucking, K., Richey, J.M., Kabir, M., Bergman, R.N. Diabetes (2005) [Pubmed]
  18. Risperidone for the core symptom domains of autism: results from the study by the autism network of the research units on pediatric psychopharmacology. McDougle, C.J., Scahill, L., Aman, M.G., McCracken, J.T., Tierney, E., Davies, M., Arnold, L.E., Posey, D.J., Martin, A., Ghuman, J.K., Shah, B., Chuang, S.Z., Swiezy, N.B., Gonzalez, N.M., Hollway, J., Koenig, K., McGough, J.J., Ritz, L., Vitiello, B. The American journal of psychiatry. (2005) [Pubmed]
  19. Growth and sexual maturation during long-term treatment with risperidone. Dunbar, F., Kusumakar, V., Daneman, D., Schulz, M. The American journal of psychiatry. (2004) [Pubmed]
  20. Effects of elevated serum prolactin on bone mineral density and bone metabolism in female patients with schizophrenia: a prospective study. Abraham, G., Paing, W.W., Kaminski, J., Joseph, A., Kohegyi, E., Josiassen, R.C. The American journal of psychiatry. (2003) [Pubmed]
  21. DRD2 promoter region variation as a predictor of sustained response to antipsychotic medication in first-episode schizophrenia patients. Lencz, T., Robinson, D.G., Xu, K., Ekholm, J., Sevy, S., Gunduz-Bruce, H., Woerner, M.G., Kane, J.M., Goldman, D., Malhotra, A.K. The American journal of psychiatry. (2006) [Pubmed]
  22. Differences in frontal cortical activation by a working memory task after substitution of risperidone for typical antipsychotic drugs in patients with schizophrenia. Honey, G.D., Bullmore, E.T., Soni, W., Varatheesan, M., Williams, S.C., Sharma, T. Proc. Natl. Acad. Sci. U.S.A. (1999) [Pubmed]
  23. An MRI study of basal ganglia volumes in first-episode schizophrenia patients treated with risperidone. Lang, D.J., Kopala, L.C., Vandorpe, R.A., Rui, Q., Smith, G.N., Goghari, V.M., Honer, W.G. The American journal of psychiatry. (2001) [Pubmed]
  24. Reduced basal ganglia volumes after switching to olanzapine in chronically treated patients with schizophrenia. Lang, D.J., Kopala, L.C., Vandorpe, R.A., Rui, Q., Smith, G.N., Goghari, V.M., Lapointe, J.S., Honer, W.G. The American journal of psychiatry. (2004) [Pubmed]
  25. The 5-HT2 antagonist ritanserin blocks dopamine re-uptake in the rat frontal cortex. Ruiu, S., Marchese, G., Saba, P.L., Gessa, G.L., Pani, L. Mol. Psychiatry (2000) [Pubmed]
  26. Immediate effects of risperidone on cortico-striato-thalamic loops and the hippocampus. Liddle, P.F., Lane, C.J., Ngan, E.T. The British journal of psychiatry : the journal of mental science. (2000) [Pubmed]
  27. Suggested minimal effective dose of risperidone based on PET-measured D2 and 5-HT2A receptor occupancy in schizophrenic patients. Nyberg, S., Eriksson, B., Oxenstierna, G., Halldin, C., Farde, L. The American journal of psychiatry. (1999) [Pubmed]
  28. Antipsychotic drugs antagonize human serotonin type 3 receptor currents in a noncompetitive manner. Rammes, G., Eisensamer, B., Ferrari, U., Shapa, M., Gimpl, G., Gilling, K., Parsons, C., Riering, K., Hapfelmeier, G., Bondy, B., Zieglgänsberger, W., Holsboer, F., Rupprecht, R. Mol. Psychiatry (2004) [Pubmed]
  29. Predominant role of the 9-hydroxy metabolite of risperidone in elevating blood prolactin levels. Knegtering, R., Baselmans, P., Castelein, S., Bosker, F., Bruggeman, R., van den Bosch, R.J. The American journal of psychiatry. (2005) [Pubmed]
  30. Long-acting injectable risperidone v. olanzapine tablets for schizophrenia or schizoaffective disorder. Randomised, controlled, open-label study. Keks, N.A., Ingham, M., Khan, A., Karcher, K. Br. J. Psychiatry (2007) [Pubmed]
  31. A pilot study on risperidone metabolism: the role of cytochromes P450 2D6 and 3A. Bork, J.A., Rogers, T., Wedlund, P.J., de Leon, J. The Journal of clinical psychiatry. (1999) [Pubmed]
  32. Changes in serum interleukin-2, -6, and -8 levels before and during treatment with risperidone and haloperidol: relationship to outcome in schizophrenia. Zhang, X.Y., Zhou, D.F., Cao, L.Y., Zhang, P.Y., Wu, G.Y., Shen, Y.C. The Journal of clinical psychiatry. (2004) [Pubmed]
  33. The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation. de Leon, J., Susce, M.T., Pan, R.M., Fairchild, M., Koch, W.H., Wedlund, P.J. The Journal of clinical psychiatry. (2005) [Pubmed]
  34. Variants of the dopamine D2 receptor gene and risperidone-induced hyperprolactinemia in children and adolescents. Calarge, C.A., Ellingrod, V.L., Acion, L., Miller, D.D., Moline, J., Tansey, M.J., Schlechte, J.A. Pharmacogenet. Genomics (2009) [Pubmed]
  35. Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia. Purdon, S.E., Jones, B.D., Stip, E., Labelle, A., Addington, D., David, S.R., Breier, A., Tollefson, G.D. Arch. Gen. Psychiatry (2000) [Pubmed]
  36. A PET study evaluating dopamine D2 receptor occupancy for long-acting injectable risperidone. Remington, G., Mamo, D., Labelle, A., Reiss, J., Shammi, C., Mannaert, E., Mann, S., Kapur, S. The American journal of psychiatry. (2006) [Pubmed]
WikiGenes - Universities